Cannabinoid Agonists Pipeline Insights 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Cannabinoid Agonists - Pipeline Insights, 2017" drug pipelines to their offering.

Cannabinoid Agonists - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Cannabinoid Agonists. This report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Cannabinoid Agonists.

This report also assesses the Cannabinoid Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Scope:

  • The report provides competitive pipeline landscape of Cannabinoid Agonists
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Cannabinoid Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Cannabinoid Agonists and also provides company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Cannabinoid Agonists Overview
  2. Cannabinoid Agonists Pipeline Therapeutics
  3. Cannabinoid Agonists Therapeutics under Development by Companies
  4. Cannabinoid Agonists Filed and Phase III Products
  5. Cannabinoid Agonists Phase II Products
  6. Cannabinoid Agonists Phase I and IND Filed Products
  7. Cannabinoid Agonists Discovery and Pre-Clinical Stage Products
  8. Drug Candidate Profiles
  9. Cannabinoid Agonists - Therapeutics Assessment
  10. Companies Involved in Therapeutics Development for Cannabinoid Agonists
  11. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/pwzvtz/cannabinoid

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs